Rheumatology

Your Article Summary

See Latest Articles

Novel treatments for systemic amyloidosis
International Journal of Clinical Rheumatology, 05/07/09

van Gameren II et al. – Article reviews the current treatments for systemic amyloidoses:

• Current treatment is directed against an ongoing supply of precursor proteins
• Treatment modalities include:
  • liver transplantation for transthyretin-related (ATTR) amyloidosis
  • elimination of inflammation in amyloid A (AA) amyloidosis and
  • intensive chemotherapy in immunoglobulin light chain (AL) amyloidosis
• These therapies often elicit substantial morbidity and mortality or insufficient effectiveness
• Therefore, the search for new, more effective therapies without serious side-effects remains mandatory
• Since cardiac involvement is vital when deciding on therapy, the introduction of N-terminal probrain natriuretic peptide (NT-proBNP) and troponin are of great importance
• New potent precursor-lowering drugs, such as thalidomide, lenalidomide and bortezomib, need to find their place in treatment protocols in AL amyloidosis
  
  

  << Previous MRI predicts response to anti-TNF in ankylosing spondylitis

  Next >> Bone mineral density in estrogen deficient young women

  Today in Amyloidosis...keeping you current

  Receive free subspecialty "5-minute updates" via email

  A case with rheumatoid arthritis and systemic reactive AA amyloidosis showing rapid regression of amyloid deposition on gastroduodenal mucosa after a combined therapy of corticosteroid and etanercept
  Rheumatology International, 10/16/09

  Left Ventricular Ejection Time on Echocardiography Predicts Long-Term Mortality in Light Chain Amyloidosis
  Journal of the American Society of Echocardiography, 11/04/09

  MEFV mutations in Egyptian patients suffering from familial Mediterranean fever: analysis of 12 gene mutations
  Rheumatology International, 10/16/09

  See All of Amyloidosis
  
  Sponsor